Approximately 10ml of peripheral blood or 3ml plasma.
Lepu Medical has developed a methylated genes product for lung cancer detection.
Only a tube of blood is needed for the non-invasive diagnostic tests.
The Diagnostics kits of methylated genes of lung cancer are relied on a blood-based test and combine with proprietary epigenomics ctDNA methylation biomarkers for diagnosis of lung cancer, also known as abnormal gene epigenetic modification. Lung cancer diagnostic kits as an auxiliary screening technique can alleviate and avoid patient anxiety during times of uncertain results, assist the doctors with a clinical diagnosis of diseases, providing doctors with a fast, accurate, and reliable method to diagnose cancer.
The Diagnostics kits can be used for lung cancer screening by detecting abnormal methylation levels of ctDNA. It can predict the development of cancer and monitor cancer metastasis and recurrence.
The Diagnostics kits can be used at various stages of cancer development.
*Disclaimer:
LEPU Medical applied methlylation markers to auxiliary diagnose lung cancer.[3][4]
Picture shown for illustrative purposes only.
Lung cancer is the 2nd most common cancer and the most deadly cancer worldwide. According to Global Cancer Statistics 2020, the incidence rate of lung cancer is about 11.4%[1].
Lung cancer is cancer with the greatest economic impact and the greatest number of years of life lost worldwide[2].
Lepu Medical has developed the advanced MSP+MethylLight technology for auxiliary diagnosis of cancer.
Smoking history (including current or former smokers) or smoke exposure (passive smoking).
Male and female aged 40 and above.
Been diagnosed with a pulmonary nodule.
Been diagnosed with other lung diseases, like chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, etc.
Family history of lung cancer in first-degree relatives.
Occupational exposures (Especially occupations identified as having targeted lung carcinogens).
The whole diagnosis process <7 hours.
Reference
[1] Sung H , Ferlay J , Siegel R L , et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incide
nce and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA: A Cancer Journal for Clinicians, 2021, 71(3):209-249.
[2] THE GLOBAL ECONOMIC COST OF CANCER,American Cancer Society, http://phrma-docs.phrma.org/sites/default/files/pdf/08-17-2010_economic_impact_study.pdf.
[1] Wei B , Wu F , Xing W , et al. A Panel of DNA Methylation Biomarkers for Detection and Improving Diagnostic Efficiency of Lung Cancer[J]. Scientific Reports.
[2] Xing W , Sun H , Yan C , et al. A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules[J]. BMC Cancer, 2021, 21(1).
Approximately 10ml of peripheral blood or 3ml plasma.
Packaging Specifications of the test kits are 30 tests/ kit.
It is required to use a software (which is provided with kit), input result from qPCR, then user will get detection value. The presentation states that a negative result is considered when detection values are <2.0 and a positive result when detection values ≥2.0.
*Product registration and availability vary by country. For more information on product availability, please contact us here.